USD 5.45
(-0.55%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 | 3.28 Billion SEK | 27.86% |
2023 | 2.57 Billion SEK | -7.51% |
2022 | 2.68 Billion SEK | -12.36% |
2021 | 3.06 Billion SEK | 4.21% |
2020 | 2.94 Billion SEK | 9.65% |
2019 | 2.67 Billion SEK | 20.58% |
2018 | 2.22 Billion SEK | 29.27% |
2017 | 1.2 Billion SEK | 3.67% |
2016 | 1.06 Billion SEK | 14.71% |
2015 | 1.44 Billion SEK | -36.46% |
2014 | 2.11 Billion SEK | -5.75% |
2013 | 2.33 Billion SEK | 10.36% |
2012 | 2.2 Billion SEK | 24.28% |
2011 | 1.76 Billion SEK | 19.85% |
2010 | 1.47 Billion SEK | 35.08% |
2009 | 1.08 Billion SEK | 37.15% |
2008 | 794 Million SEK | 11.2% |
2007 | 714 Million SEK | 5.93% |
2006 | 674 Million SEK | 42.19% |
2005 | 474 Million SEK | 29.16% |
2004 | 367 Million SEK | -1.61% |
2003 | 373 Million SEK | 47.43% |
2002 | 253 Million SEK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 857 Million SEK | 24.75% |
2024 Q4 | 858 Million SEK | 3.39% |
2024 Q1 | 723 Million SEK | -33.41% |
2024 Q3 | 794 Million SEK | 4.08% |
2024 FY | - SEK | 40.71% |
2023 Q1 | 447 Million SEK | -55.43% |
2023 Q2 | 608 Million SEK | 36.02% |
2023 Q4 | 700 Million SEK | -4.5% |
2023 Q3 | 733 Million SEK | 20.56% |
2023 FY | - SEK | -7.51% |
2022 Q1 | 405 Million SEK | -50.06% |
2022 Q3 | 547 Million SEK | -25.27% |
2022 FY | - SEK | -12.36% |
2022 Q4 | 1 Billion SEK | 83.36% |
2022 Q2 | 732 Million SEK | 80.74% |
2021 Q2 | 803 Million SEK | 13.74% |
2021 Q1 | 706 Million SEK | -26.38% |
2021 Q4 | 811 Million SEK | 8.42% |
2021 Q3 | 748 Million SEK | -6.85% |
2021 FY | - SEK | 4.21% |
2020 Q2 | 662 Million SEK | 16.75% |
2020 Q4 | 959 Million SEK | 27.02% |
2020 Q1 | 567 Million SEK | -44.3% |
2020 Q3 | 755 Million SEK | 14.05% |
2020 FY | - SEK | 9.65% |
2019 Q2 | 658 Million SEK | 47.2% |
2019 Q4 | 1.01 Billion SEK | 82.76% |
2019 Q3 | 557 Million SEK | -15.35% |
2019 Q1 | 447 Million SEK | -52.29% |
2019 FY | - SEK | 20.58% |
2018 Q2 | 547 Million SEK | 148.64% |
2018 FY | - SEK | 29.27% |
2018 Q1 | 220 Million SEK | -71.17% |
2018 Q4 | 937 Million SEK | 77.13% |
2018 Q3 | 529 Million SEK | -3.29% |
2017 Q1 | 210 Million SEK | -72.22% |
2017 Q4 | 763 Million SEK | 125.07% |
2017 FY | - SEK | 3.67% |
2017 Q3 | 339 Million SEK | -18.12% |
2017 Q2 | 414 Million SEK | 97.14% |
2016 Q3 | 319 Million SEK | -35.69% |
2016 FY | - SEK | 14.71% |
2016 Q1 | 90 Million SEK | -85.32% |
2016 Q4 | 756 Million SEK | 136.99% |
2016 Q2 | 496 Million SEK | 451.11% |
2015 FY | - SEK | -36.46% |
2015 Q4 | 613 Million SEK | 57.99% |
2015 Q3 | 388 Million SEK | -12.42% |
2015 Q2 | 443 Million SEK | 10975.0% |
2015 Q1 | 4 Million SEK | -99.69% |
2014 Q4 | 1.29 Billion SEK | 253.68% |
2014 FY | - SEK | -5.75% |
2014 Q1 | 175 Million SEK | -85.37% |
2014 Q2 | 439 Million SEK | 150.86% |
2014 Q3 | 367 Million SEK | -16.4% |
2013 Q4 | 1.19 Billion SEK | 209.84% |
2013 FY | - SEK | 10.36% |
2013 Q1 | 62 Million SEK | -91.18% |
2013 Q2 | 502 Million SEK | 709.68% |
2013 Q3 | 386 Million SEK | -23.11% |
2012 Q1 | 103 Million SEK | -86.57% |
2012 Q3 | 639 Million SEK | 58.17% |
2012 Q2 | 404 Million SEK | 292.23% |
2012 Q4 | 703 Million SEK | 10.02% |
2012 FY | - SEK | 24.28% |
2011 Q2 | 303 Million SEK | 89.38% |
2011 FY | - SEK | 19.85% |
2011 Q1 | 160 Million SEK | -76.4% |
2011 Q3 | 292 Million SEK | -3.63% |
2011 Q4 | 767 Million SEK | 162.67% |
2010 Q2 | 240 Million SEK | 147.42% |
2010 Q1 | 97 Million SEK | 0.0% |
2010 Q3 | 227 Million SEK | -5.42% |
2010 FY | - SEK | 35.08% |
2010 Q4 | 678 Million SEK | 198.68% |
2009 FY | - SEK | 37.15% |
2008 FY | - SEK | 11.2% |
2007 FY | - SEK | 5.93% |
2006 FY | - SEK | 42.19% |
2005 FY | - SEK | 29.16% |
2004 FY | - SEK | -1.61% |
2003 FY | - SEK | 47.43% |
2002 FY | - SEK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
American Medical Technologies Inc. | -963.95 Thousand USD | 340987.636% |
Ansell Limited | 209.86 Million USD | -1465.796% |
Ansell Limited | 206.3 Million USD | -1492.826% |
BG Medicine, Inc. | - USD | -Infinity% |
Biotage AB (publ) | 42.83 Million USD | -7570.437% |
BioLife Sciences Inc. | - USD | -Infinity% |
CB Scientific, Inc. | -1.62 Million USD | 202321.482% |
Psykey, Inc. | -1.29 Million USD | 253785.621% |
ConvaTec Group Plc | 455.5 Million USD | -621.405% |
ConvaTec Group Plc | 455.5 Million USD | -621.405% |
Encision Inc. | -544.19 Thousand USD | 603927.672% |
Golden Valley Development, Inc | -141.81 Thousand USD | 2317284.966% |
Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 2989274.93% |
Innovative MedTech Inc. | -7.67 Million USD | 42920.933% |
LifePoint, Inc. | -14.2 Million USD | 23237.363% |
Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 53211.363% |
Paradigm Medical Industries, Inc. | -325 Thousand USD | 1011176.923% |
QuantRx Biomedical Corporation | - USD | -Infinity% |
Remedent, Inc. | -215.23 Thousand USD | 1526810.464% |
Reflect Scientific, Inc. | -405.78 Thousand USD | 809890.43% |
SmileDirectClub, Inc. | -186.13 Million USD | 1865.347% |
Sector 10, Inc. | - USD | -Infinity% |
Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | -633.77% |
SheerVision, Inc. | -110.53 Thousand USD | 2973021.624% |
United Health Products, Inc. | -2.5 Million USD | 131423.7% |
Vasamed, Inc. | -4.57 Million USD | 71933.898% |
Wearable Health Solutions, Inc. | -2.26 Million USD | 145450.895% |
Yubo International Biotech Limited | -1.17 Million USD | 279121.743% |